Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis

<p>Abstract</p> <p>Background</p> <p>Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics. In the present study, the combined impact of the mammalian target of rapamycin (mTOR)-inhibitor RAD001...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Waaga-Gasser Ana, Tsaur Igor, Juengel Eva, Makarević Jasmina, Seibel Jens-Michael, Hudak Lukasz, Wedel Steffen, Haferkamp Axel, Blaheta Roman A
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2011-08-01
Rangatū:	BMC Cancer
Urunga tuihono:	http://www.biomedcentral.com/1471-2407/11/375
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!